LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 18

Search options

  1. Article ; Online: Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.

    Aguinam, Ernest T / Nadesalingam, Angalee / Chan, Andrew / Smith, Peter / Paloniemi, Minna / Cantoni, Diego / Gronlund, Jessica / Gronlund, Helen / Carnell, George W / Castillo-Olivares, Javier / Temperton, Nigel / Blacklaws, Barbara / Heeney, Jonathan L / Baxendale, Helen

    The journal of allergy and clinical immunology. Global

    2023  Volume 2, Issue 2, Page(s) 100091

    Abstract: Background: Immunodeficient patients (IDPs) are at higher risk of contracting severe coronavirus disease 2019 (COVID-19). Targeted vaccination strategies have been implemented to enhance vaccine-induced protection. In this population, however, clinical ... ...

    Abstract Background: Immunodeficient patients (IDPs) are at higher risk of contracting severe coronavirus disease 2019 (COVID-19). Targeted vaccination strategies have been implemented to enhance vaccine-induced protection. In this population, however, clinical effectiveness is variable and the duration of protection unknown.
    Objective: We sought to better understand the cellular and humoral immune responses to mRNA and adenoviral vectored COVID-19 vaccines in patients with immunodeficiency.
    Methods: Immune responses to severe acute respiratory syndrome coronavirus 2 spike were assessed after 2 doses of homologous ChAdOx1-nCoV-19 or BNT162b2 vaccines in 112 infection-naive IDPs and 131 healthy health care workers as controls. Predictors of vaccine responsiveness were investigated.
    Results: Immune responses to vaccination were low, and virus neutralization by antibody was not detected despite high titer binding responses in many IDPs. In those exhibiting response, the frequency of specific T-cell responses in IDPs was similar to controls, while antibody responses were lower. Sustained vaccine specific differences were identified: T-cell responses were greater in ChAdOx1-nCoV-19- compared to BNT162b2-immunized IDPs, and antibody binding and neutralization were greater in all cohorts immunized with BNT162b2. The positive correlation between T-cell and antibody responses was weak and increased with subsequent vaccination.
    Conclusion: Immunodeficient patients have impaired immune responses to mRNA and viral vector COVID-19 vaccines that appear to be influenced by vaccine formulation. Understanding the relative roles of T-cell- and antibody-mediated protection as well as the potential of heterologous prime and boost immunization protocols is needed to optimize the vaccination approach in these high-risk groups.
    Language English
    Publishing date 2023-03-15
    Publishing country United States
    Document type Journal Article
    ISSN 2772-8293
    ISSN (online) 2772-8293
    DOI 10.1016/j.jacig.2023.100091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies.

    Nadesalingam, Angalee / Cantoni, Diego / Aguinam, Ernest T / Chan, Andrew Cy / Paloniemi, Minna / Ohlendorf, Luis / George, Charlotte / Carnell, George / Lyall, Jon / Ferrari, Matteo / Temperton, Nigel / Wagner, Ralf / Castillo-Olivares, Javier / Baxendale, Helen / Heeney, Jonathan L

    The Lancet. Microbe

    2022  Volume 4, Issue 2, Page(s) e58–e59

    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19/prevention & control ; Immunologic Deficiency Syndromes ; Vaccination
    Language English
    Publishing date 2022-11-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2666-5247
    ISSN (online) 2666-5247
    DOI 10.1016/S2666-5247(22)00297-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients.

    Cantoni, Diego / Mayora-Neto, Martin / Thakur, Nazia / Elrefaey, Ahmed M E / Newman, Joseph / Vishwanath, Sneha / Nadesalingam, Angalee / Chan, Andrew / Smith, Peter / Castillo-Olivares, Javier / Baxendale, Helen / Charleston, Bryan / Heeney, Jonathan / Bailey, Dalan / Temperton, Nigel

    Communications biology

    2022  Volume 5, Issue 1, Page(s) 409

    Abstract: RaTG13 is a close relative of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, sharing 96% sequence similarity at the genome-wide level. The spike receptor binding domain (RBD) of RaTG13 contains a number of amino acid substitutions when ... ...

    Abstract RaTG13 is a close relative of SARS-CoV-2, the virus responsible for the COVID-19 pandemic, sharing 96% sequence similarity at the genome-wide level. The spike receptor binding domain (RBD) of RaTG13 contains a number of amino acid substitutions when compared to SARS-CoV-2, likely impacting affinity for the ACE2 receptor. Antigenic differences between the viruses are less well understood, especially whether RaTG13 spike can be efficiently neutralised by antibodies generated from infection with, or vaccination against, SARS-CoV-2. Using RaTG13 and SARS-CoV-2 pseudotypes we compared neutralisation using convalescent sera from previously infected patients or vaccinated healthcare workers. Surprisingly, our results revealed that RaTG13 was more efficiently neutralised than SARS-CoV-2. In addition, neutralisation assays using spike mutants harbouring single and combinatorial amino acid substitutions within the RBD demonstrated that both spike proteins can tolerate multiple changes without dramatically reducing neutralisation. Moreover, introducing the 484 K mutation into RaTG13 resulted in increased neutralisation, in contrast to the same mutation in SARS-CoV-2 (E484K). This is despite E484K having a well-documented role in immune evasion in variants of concern (VOC) such as B.1.351 (Beta). These results indicate that the future spill-over of RaTG13 and/or related sarbecoviruses could be mitigated using current SARS-CoV-2-based vaccination strategies.
    MeSH term(s) Animals ; COVID-19/therapy ; Chiroptera/metabolism ; Humans ; Immunization, Passive ; Membrane Glycoproteins/metabolism ; Pandemics ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; Viral Envelope Proteins/genetics ; COVID-19 Serotherapy
    Chemical Substances Membrane Glycoproteins ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2022-05-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2399-3642
    ISSN (online) 2399-3642
    DOI 10.1038/s42003-022-03325-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Human seasonal coronavirus neutralization and COVID-19 severity.

    Wells, David A / Cantoni, Diego / Mayora-Neto, Martin / Genova, Cecilia Di / Sampson, Alexander / Ferrari, Matteo / Carnell, George / Nadesalingam, Angalee / Smith, Peter / Chan, Andrew / Raddi, Gianmarco / Castillo-Olivares, Javier / Baxendale, Helen / Temperton, Nigel / Heeney, Jonathan L

    Journal of medical virology

    2022  Volume 94, Issue 10, Page(s) 4820–4829

    Abstract: The virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the global coronavirus disease-2019 (COVID-19) pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic ... ...

    Abstract The virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the global coronavirus disease-2019 (COVID-19) pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs), and whether antibodies for these HCoVs play a role in severity of COVID-19 disease has generated a lot of interest. Of these seasonal viruses NL63 is of particular interest as it uses the same cell entry receptor as SARS-CoV-2. We use functional, neutralizing assays to investigate cross-reactive antibodies and their relationship with COVID-19 severity. We analyzed the neutralization of SARS-CoV-2, NL63, HKU1, and 229E in 38 COVID-19 patients and 62 healthcare workers, and a further 182 samples to specifically study the relationship between SARS-CoV-2 and NL63. We found that although HCoV neutralization was very common there was little evidence that these antibodies neutralized SARS-CoV-2. Despite no evidence in cross-neutralization, levels of NL63 neutralizing antibodies become elevated after exposure to SARS-CoV-2 through infection or following vaccination.
    MeSH term(s) Antibodies, Viral ; COVID-19 ; Coronavirus NL63, Human ; Cross Reactions ; Humans ; Pandemics ; SARS-CoV-2 ; Seasons ; Spike Glycoprotein, Coronavirus
    Chemical Substances Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2022-07-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.27937
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.

    Nadesalingam, Angalee / Cantoni, Diego / Wells, David A / Aguinam, Ernest T / Ferrari, Matteo / Smith, Peter / Chan, Andrew / Carnell, George / Ohlendorf, Luis / Einhauser, Sebastian / George, Charlotte / Wagner, Ralf / Temperton, Nigel / Castillo-Olivares, Javier / Baxendale, Helen / Heeney, Jonathan L

    The Lancet. Microbe

    2021  Volume 2, Issue 9, Page(s) e416–e418

    MeSH term(s) Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral ; COVID-19/prevention & control ; Humans ; SARS-CoV-2 ; United Kingdom/epidemiology
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2021-06-28
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2666-5247
    ISSN (online) 2666-5247
    DOI 10.1016/S2666-5247(21)00157-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds.

    Cantoni, Diego / Mayora-Neto, Martin / Nadesalingam, Angalee / Wells, David A / Carnell, George W / Ohlendorf, Luis / Ferrari, Matteo / Palmer, Phil / Chan, Andrew C Y / Smith, Peter / Bentley, Emma M / Einhauser, Sebastian / Wagner, Ralf / Page, Mark / Raddi, Gianmarco / Baxendale, Helen / Castillo-Olivares, Javier / Heeney, Jonathan / Temperton, Nigel

    Frontiers in immunology

    2022  Volume 13, Page(s) 773982

    Abstract: The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used ... ...

    Abstract The rise of SARS-CoV-2 variants has made the pursuit to define correlates of protection more troublesome, despite the availability of the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin sera, a key reagent used to standardise laboratory findings into an international unitage. Using pseudotyped virus, we examine the capacity of convalescent sera, from a well-defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK to neutralise B.1.1.298, variants of interest (VOI) B.1.617.1 (Kappa), and four VOCs, B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta), including the B.1.617.2 K417N, informally known as Delta Plus. We utilised the WHO International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation antibody levels in International Units per mL. Our data demonstrate a significant reduction in the ability of first wave convalescent sera to neutralise the VOCs. Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Using an estimated threshold for 50% protection, 54 IU/mL, we found most asymptomatic and mild cases did not produce titres above this threshold.
    MeSH term(s) Antibodies, Viral ; COVID-19/therapy ; Humans ; Immunization, Passive ; SARS-CoV-2/genetics ; Severity of Illness Index
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2022-03-07
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.773982
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses.

    Vishwanath, Sneha / Carnell, George William / Ferrari, Matteo / Asbach, Benedikt / Billmeier, Martina / George, Charlotte / Sans, Maria Suau / Nadesalingam, Angalee / Huang, Chloe Qingzhou / Paloniemi, Minna / Stewart, Hazel / Chan, Andrew / Wells, David Arthur / Neckermann, Patrick / Peterhoff, David / Einhauser, Sebastian / Cantoni, Diego / Neto, Martin Mayora / Jordan, Ingo /
    Sandig, Volker / Tonks, Paul / Temperton, Nigel / Frost, Simon / Sohr, Katharina / Ballesteros, Maria Teresa Lluesma / Arbabi, Farzad / Geiger, Johannes / Dohmen, Christian / Plank, Christian / Kinsley, Rebecca / Wagner, Ralf / Heeney, Jonathan Luke

    Nature biomedical engineering

    2023  

    Abstract: The threat of spillovers of coronaviruses associated with the severe acute respiratory syndrome (SARS) from animals to humans necessitates vaccines that offer broader protection from sarbecoviruses. By leveraging a viral-genome-informed computational ... ...

    Abstract The threat of spillovers of coronaviruses associated with the severe acute respiratory syndrome (SARS) from animals to humans necessitates vaccines that offer broader protection from sarbecoviruses. By leveraging a viral-genome-informed computational method for selecting immune-optimized and structurally engineered antigens, here we show that a single antigen based on the receptor binding domain of the spike protein of sarbecoviruses elicits broad humoral responses against SARS-CoV-1, SARS-CoV-2, WIV16 and RaTG13 in mice, rabbits and guinea pigs. When administered as a DNA immunogen or by a vector based on a modified vaccinia virus Ankara, the optimized antigen induced vaccine protection from the Delta variant of SARS-CoV-2 in mice genetically engineered to express angiotensin-converting enzyme 2 and primed by a viral-vector vaccine (AZD1222) against SARS-CoV-2. A vaccine formulation incorporating mRNA coding for the optimized antigen further validated its broad immunogenicity. Vaccines that elicit broad immune responses across subgroups of coronaviruses may counteract the threat of zoonotic spillovers of betacoronaviruses.
    Language English
    Publishing date 2023-09-25
    Publishing country England
    Document type Journal Article
    ISSN 2157-846X
    ISSN (online) 2157-846X
    DOI 10.1038/s41551-023-01094-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

    Carnell, George W / Billmeier, Martina / Vishwanath, Sneha / Suau Sans, Maria / Wein, Hannah / George, Charlotte L / Neckermann, Patrick / Del Rosario, Joanne Marie M / Sampson, Alexander T / Einhauser, Sebastian / Aguinam, Ernest T / Ferrari, Matteo / Tonks, Paul / Nadesalingam, Angalee / Schütz, Anja / Huang, Chloe Qingzhou / Wells, David A / Paloniemi, Minna / Jordan, Ingo /
    Cantoni, Diego / Peterhoff, David / Asbach, Benedikt / Sandig, Volker / Temperton, Nigel / Kinsley, Rebecca / Wagner, Ralf / Heeney, Jonathan L

    Frontiers in immunology

    2023  Volume 14, Page(s) 1118523

    Abstract: The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike ...

    Abstract The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA viruses, new variants have evolved and quickly replaced the original wild-type SARS-CoV-2, leading to escape from natural infection or vaccine induced immunity provided by the original SARS-CoV-2 spike sequence. Next generation vaccines that confer specific and targeted immunity to broadly neutralising epitopes on the SARS-CoV-2 spike protein against different variants of concern (VOC) offer an advance on current booster shots of previously used vaccines. Here, we present a targeted approach to elicit antibodies that neutralise both the ancestral SARS-CoV-2, and the VOCs, by introducing a specific glycosylation site on a non-neutralising epitope of the RBD. The addition of a specific glycosylation site in the RBD based vaccine candidate focused the immune response towards other broadly neutralising epitopes on the RBD. We further observed enhanced cross-neutralisation and cross-binding using a DNA-MVA CR19 prime-boost regime, thus demonstrating the superiority of the glycan engineered RBD vaccine candidate across two platforms and a promising candidate as a broad variant booster vaccine.
    MeSH term(s) Humans ; Epitopes ; SARS-CoV-2 ; COVID-19 ; COVID-19 Vaccines ; Polysaccharides ; Antibodies, Neutralizing
    Chemical Substances Epitopes ; spike protein, SARS-CoV-2 ; COVID-19 Vaccines ; Polysaccharides ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-02-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1118523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Immunological insights into COVID-19 in Southern Nigeria.

    Ugwu, Chinedu A / Alao, Oluwasina / John, Oluwagboadurami G / Akinnawo, Blossom / Ajayi, Israel / Odebode, Ooreofe / Bejide, Ifeoluwa / Campbell, Allan / Campbell, Julian / Adole, Jolly A / B Olawoye, Idowu / Akano, Kazeem / Okolie, Johnson / Eromon, Philomena / Olaitan, Peter / Olagunoye, Ajibola / Adebayo, Ibukun / Adebayo, Victor / Babalola, Elizabeth /
    Abioye, Omowumi / Ajayi, Nnennaya / Ogah, Emeka / Ukwaja, Kingsley / Okoro, Sylvanus / Oje, Ogbonnaya / Kingsley, Ojide Chiedozie / Eke, Matthew / Onyia, Venatius / Achonduh-Atijegbe, Olivia / Ewah, Friday Elechi / Obasi, Mary / Igwe, Violet / Ayodeji, Olufemi / Chukwuyem, Abejegah / Owhin, Sampson / Oyejide, Nicholas / Abah, Sylvester / Ingbian, Winifred / Osoba, Moyosoore / Alebiosu, Ahmed / Nadesalingam, Angalee / Aguinam, Ernest T / Carnell, George / Krause, Nina / Chan, Andrew / George, Charlotte / Kinsley, Rebecca / Tonks, Paul / Temperton, Nigel / Heeney, Jonathan / Happi, Christian

    Frontiers in immunology

    2024  Volume 15, Page(s) 1305586

    Abstract: Introduction: One of the unexpected outcomes of the COVID-19 pandemic was the relatively low levels of morbidity and mortality in Africa compared to the rest of the world. Nigeria, Africa's most populous nation, accounted for less than 0.01% of the ... ...

    Abstract Introduction: One of the unexpected outcomes of the COVID-19 pandemic was the relatively low levels of morbidity and mortality in Africa compared to the rest of the world. Nigeria, Africa's most populous nation, accounted for less than 0.01% of the global COVID-19 fatalities. The factors responsible for Nigeria's relatively low loss of life due to COVID-19 are unknown. Also, the correlates of protective immunity to SARS-CoV-2 and the impact of pre-existing immunity on the outcome of the COVID-19 pandemic in Africa are yet to be elucidated. Here, we evaluated the natural and vaccine-induced immune responses from vaccinated, non-vaccinated and convalescent individuals in Southern Nigeria throughout the three waves of the COVID-19 pandemic in Nigeria. We also examined the pre-existing immune responses to SARS-CoV-2 from samples collected prior to the COVID-19 pandemic.
    Methods: We used spike RBD and N- IgG antibody ELISA to measure binding antibody responses, SARS-CoV-2 pseudotype assay protocol expressing the spike protein of different variants (D614G, Delta, Beta, Omicron BA1) to measure neutralizing antibody responses and nucleoprotein (N) and spike (S1, S2) direct ex vivo interferon gamma (IFNγ) T cell ELISpot to measure T cell responses.
    Result: Our study demonstrated a similar magnitude of both binding (N-IgG (74% and 62%), S-RBD IgG (70% and 53%) and neutralizing (D614G (49% and 29%), Delta (56% and 47%), Beta (48% and 24%), Omicron BA1 (41% and 21%)) antibody responses from symptomatic and asymptomatic survivors in Nigeria. A similar magnitude was also seen among vaccinated participants. Interestingly, we revealed the presence of preexisting binding antibodies (N-IgG (60%) and S-RBD IgG (44%)) but no neutralizing antibodies from samples collected prior to the pandemic.
    Discussion: These findings revealed that both vaccinated, non-vaccinated and convalescent individuals in Southern Nigeria make similar magnitude of both binding and cross-reactive neutralizing antibody responses. It supported the presence of preexisting binding antibody responses among some Nigerians prior to the COVID-19 pandemic. Lastly, hybrid immunity and heterologous vaccine boosting induced the strongest binding and broadly neutralizing antibody responses compared to vaccine or infection-acquired immunity alone.
    MeSH term(s) Humans ; Antibodies, Neutralizing ; Broadly Neutralizing Antibodies ; COVID-19/immunology ; Enzyme-Linked Immunospot Assay ; Immunoglobulin G ; Nigeria ; Pandemics ; SARS-CoV-2 ; West African People
    Chemical Substances Antibodies, Neutralizing ; Broadly Neutralizing Antibodies ; Immunoglobulin G
    Language English
    Publishing date 2024-01-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1305586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Evasion of Neutrophil Extracellular Traps by Respiratory Pathogens.

    Storisteanu, Daniel M L / Pocock, Joanna M / Cowburn, Andrew S / Juss, Jatinder K / Nadesalingam, Angalee / Nizet, Victor / Chilvers, Edwin R

    American journal of respiratory cell and molecular biology

    2016  Volume 56, Issue 4, Page(s) 423–431

    Abstract: The release of neutrophil extracellular traps (NETs) is a major immune mechanism intended to capture pathogens. These histone- and protease-coated DNA structures are released by neutrophils in response to a variety of stimuli, including respiratory ... ...

    Abstract The release of neutrophil extracellular traps (NETs) is a major immune mechanism intended to capture pathogens. These histone- and protease-coated DNA structures are released by neutrophils in response to a variety of stimuli, including respiratory pathogens, and have been identified in the airways of patients with respiratory infection, cystic fibrosis, acute lung injury, primary graft dysfunction, and chronic obstructive pulmonary disease. NET production has been demonstrated in the lungs of mice infected with Staphylococcus aureus, Klebsiella pneumoniae, and Aspergillus fumigatus. Since the discovery of NETs over a decade ago, evidence that "NET evasion" might act as an immune protection strategy among respiratory pathogens, including group A Streptococcus, Bordetella pertussis, and Haemophilus influenzae, has been growing, with the majority of these studies being published in the past 2 years. Evasion strategies fall into three main categories: inhibition of NET release by down-regulating host inflammatory responses; degradation of NETs using pathogen-derived DNases; and resistance to the microbicidal components of NETs, which involves a variety of mechanisms, including encapsulation. Hence, the evasion of NETs appears to be a widespread strategy to allow pathogen proliferation and dissemination, and is currently a topic of intense research interest. This article outlines the evidence supporting the three main strategies of NET evasion-inhibition, degradation, and resistance-with particular reference to common respiratory pathogens.
    MeSH term(s) Animals ; Extracellular Traps/immunology ; Humans ; Immune Evasion ; Lung/microbiology ; Lung/virology ; Models, Immunological
    Language English
    Publishing date 2016-11-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1025960-0
    ISSN 1535-4989 ; 1044-1549
    ISSN (online) 1535-4989
    ISSN 1044-1549
    DOI 10.1165/rcmb.2016-0193PS
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top